| Titre |
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With Relapsed/Refractory Hematologic Malignancies |
| Protocole ID |
PRT2527-02 |
| ClinicalTrials.gov ID |
NCT05665530 |
| Type(s) de cancer |
Lymphome non-hodgkinien (LNH) |
| Phase |
Phase I |
| Stade |
Récidivant/réfractaire (2ième ligne de traitement et plus) |
| Type étude |
Clinique |
| Médicament |
PRT2527 en monothérapie ou en association zanubrutinib |
| Institution |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
 HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
|
| Ville |
Montréal |
| Investigateur(trice) principal(e) |
Dre Sarit Assouline
|
| Coordonnateur(trice) |
Aline Khayat
514-340-8222
|
| Statut |
 Actif en recrutement |
| Date d'activation |
01-02-2024 |
| Critètes d'éligibilité |
- Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures
- Histologically or cytologically confirmed diagnosis of aggressive B-cell lymphoma subtypes, MCL, CLL/SLL, including Richter's syndrome, based on local testing , or TCL (monotherapy only) that have relapsed or become refractory to or be ineligible for standard-of-care therapy
- Must provide either an archival or fresh tumor tissue sample from a core or excisional/surgical biopsy
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Adequate organ function (hematology, renal, and hepatic)
- Echocardiogram (or multigated acquisition [MUGA] scan) indicating a left ventricular ejection fraction of ≥ 50%
|
| Critètes d'exclusion |
- Have active central nervous system involvement by malignancy, uncontrolled intercurrent illnesses, and active infections requiring systemic therapy
- Have undergone HSCT within the last 90 days or have graft versus host disease (GvHD) Grade > 1 at study entry
- Mean corrected QT interval of > 470 msec following triplicate ECG measurements or a history of long QT Syndrome
- Have severe pulmonary disease with hypoxemia
- History of another malignancy except for adequately treated non-melanoma skin cancer or lentigo maligna, superficial bladder cancer, and carcinoma in situ of the cervix without evidence of disease, and asymptomatic prostate cancer without known metastatic disease and no requirement for therapy
- Concurrent treatment or within 15 days of starting study treatment with strong CYP3A4 inhibitors or inducers or use of moderate CYP3A4 inducers (for combination therapy only)
- Prior exposure to a CDK9 inhibitor
- Wait at least 5 half-lives of the agent or 14 days after their investigational or approved therapies before start of study treatment, whichever is shorter
- Mean corrected QT interval of > 470 msec following triplicate ECG measurement or history of long QT syndrome
- T-Cell leukemias
|
Groupe d'étude en oncologie du Québec